Rezafungin In Vitro Activity against Contemporary Nordic Clinical Candida Isolates and Candida auris Determined by the EUCAST Reference Method

被引:50
作者
Helleberg, Marie [1 ,2 ]
Jorgensen, Karin Meinike [2 ]
Hare, Rasmus Kroger [2 ]
Datcu, Raluca [2 ]
Chowdhary, Anuradha [4 ]
Arendrup, Maiken Cavling [2 ,3 ,5 ]
机构
[1] Rigshosp, Dept Infect Dis, Copenhagen, Denmark
[2] Statens Serum Inst, Unit Mycol, Copenhagen, Denmark
[3] Rigshosp, Dept Clin Microbiol, Copenhagen, Denmark
[4] Univ Delhi, VP Chest Inst, Dept Med Mycol, Delhi, India
[5] Univ Copenhagen, Dept Clin Med, Copenhagen, Denmark
基金
新加坡国家研究基金会;
关键词
rezafungin; in vitro activity; MIC; Candida; Candida auris; EUCAST; antifungal resistance; antifungal susceptibility testing; echinocandin; LONG-ACTING ECHINOCANDIN; CD101; RESISTANCE; SPP; CLSI;
D O I
10.1128/AAC.02438-19
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Rezafungin (formerly CD101) is a novel echinocandin in clinical development. EUCAST epidemiological cutoff values (ECOFFs) have not yet been established. We determined the in vitro activity of rezafungin and comparators against 1,293 Nordic yeast isolates and 122 Indian Candida auris isolates and established single-center wild-type upper limits (WT-UL). The isolates (19 Candida spp. and 13 other yeast species) were identified using Chromagar; matrix-assisted laser desorption ionization-time of flight (MALDI-TOF); and, when needed, internal transcribed spacer sequencing. EUCAST E.Def 7.3.1 susceptibility testing included rezafungin, anidulafungin, micafungin, amphotericin B, and fluconazole. WT-UL were established following EUCAST principles for visual and statistical ECOFF setting. fks target genes were sequenced for rezafungin non-wild-type isolates. EUCAST clinical breakpoints for fungi version 9.0 were adopted for susceptibility classification. Rezafungin had species-specific activity similar to that of anidulafungin and micafungin. On a milligram-per-liter basis, rezafungin was overall less active than anidulafungin and micafungin but equally or more active than fluconazole and amphotericin B against the most common Candida species, except C. parapsilosis. We identified 37 (3.1%) rezafungin nonwild-type isolates of C albicans (1.9%), C. glabrata (3.0%), C. tropicalis (2.7%), C. dubliniensis (2.9%), C krusei (1.2%), and C. auris (14.8%). Alterations in Fks hot spots were found in 26/26 Nordic and 8/18 non-wild-type C. auris isolates. Rezafungin displayed broad in vitro activity against Candida spp., including C auris. Adopting WT-UL established here, few Nordic strains, but a significant proportion of C. auris isolates, had elevated MICs with mutations in fks target genes that conferred echinocandin cross-resistance. fks1 mutations raised rezafungin MICs notably less than anidulafungin and micafungin MICs in C. auris.
引用
收藏
页数:10
相关论文
共 20 条
[1]   Multicentre determination of rezafungin (CD101) susceptibility of Candida species by the EUCAST method [J].
Arendrup, M. C. ;
Meletiadis, J. ;
Zaragoza, O. ;
Jorgensen, K. M. ;
Marcos-Zambrano, L. J. ;
Kanioura, L. ;
Cuenca-Estrella, M. ;
Mouton, J. W. ;
Guinea, J. .
CLINICAL MICROBIOLOGY AND INFECTION, 2018, 24 (11) :1200-1204
[2]   EUCAST technical note on isavuconazole breakpoints for Aspergillus, itraconazole breakpoints for Candida and updates for the antifungal susceptibility testing method documents [J].
Arendrup, M. C. ;
Meletiadis, J. ;
Mouton, J. W. ;
Guinea, J. ;
Cuenca-Estrella, M. ;
Lagrou, K. ;
Howard, S. J. .
CLINICAL MICROBIOLOGY AND INFECTION, 2016, 22 (06) :571.e1-571.e4
[3]  
Arendrup MC, 2013, CLIN MICROBIOL INFEC, V19, pE343, DOI 10.1111/1469-0691.12212
[4]   Echinocandin resistance: an emerging clinical problem? [J].
Arendrup, Maiken C. ;
Perlin, David S. .
CURRENT OPINION IN INFECTIOUS DISEASES, 2014, 27 (06) :484-492
[5]   EUCAST Reference Testing of Rezafungin Susceptibility and Impact of Choice of Plastic Plates [J].
Arendrup, Maiken Cavling ;
Jorgensen, Karin Meinike ;
Hare, Rasmus Kroger ;
Cuenca-Estrella, Manuel ;
Zaragoza, Oscar .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2019, 63 (09)
[6]  
Arendrup MC, 2018, ANTIMICROB AGENTS CH, V62, DOI [10.1128/AAC.01225-18, 10.1128/aac.01225-18]
[7]   Echinocandin Susceptibility Testing of Candida spp. Using EUCAST EDef 7.1 and CLSI M27-A3 Standard Procedures: Analysis of the Influence of Bovine Serum Albumin Supplementation, Storage Time, and Drug Lots [J].
Arendrup, Maiken Cavling ;
Rodriguez-Tudela, Juan-Luis ;
Park, Steven ;
Garcia-Effron, Guillermo ;
Delmas, Guillaume ;
Cuenca-Estrella, Manuel ;
Gomez-Lopez, Alicia ;
Perlin, David S. .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2011, 55 (04) :1580-1587
[8]  
Bader JC, 2018, ANTIMICROB AGENTS CH, V62, DOI [10.1128/AAC.02614-17, 10.1128/aac.02614-17]
[9]   Activity of CD101, a long-acting echinocandin, against clinical isolates of Candida auris [J].
Berkow, Elizabeth L. ;
Lockhart, Shawn R. .
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2018, 90 (03) :196-197
[10]   Interlaboratory Variability of Caspofungin MICs for Candida spp. Using CLSI and EUCAST Methods: Should the Clinical Laboratory Be Testing This Agent? [J].
Espinel-Ingroff, A. ;
Arendrup, M. C. ;
Pfaller, M. A. ;
Bonfietti, L. X. ;
Bustamante, B. ;
Canton, E. ;
Chryssanthou, E. ;
Cuenca-Estrella, M. ;
Dannaoui, E. ;
Fothergill, A. ;
Fuller, J. ;
Gaustad, P. ;
Gonzalez, G. M. ;
Guarro, J. ;
Lass-Floerl, C. ;
Lockhart, S. R. ;
Meis, J. F. ;
Moore, C. B. ;
Ostrosky-Zeichner, L. ;
Pelaez, T. ;
Pukinskas, S. R. B. S. ;
St-Germain, G. ;
Szeszs, M. W. ;
Turnidge, J. .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2013, 57 (12) :5836-5842